3rd Annual AGILEDxRx Conference

Alliance for Global Implementation of Lung and Cardiac
Early Disease Detection and Treatment

49th International
Conference on Screening
for Lung Cancer

17th Conference on Early
Lung Cancer Research
on Treatment

Medical University of Gdańsk

University Clinical Center Gdańsk, Poland
Floor 1, Smoluchowskiego 17M , 80-214 Gdańsk

March 19 - 21, 2026

Event is Open to Public In-person and Virtually

REGISTRATION

The early detection of lung cancer using thoracic CT has been widely demonstrated in multiple international trials to objectively increase cure rates. Now the international focus is on effective and economical implementation. Increasingly, it is emerging that thoracic CT screening is also detecting a range of early tobacco-related diseases including cardiovascular disease and chronic obstructive pulmonary disease. These three diseases comprise the ‘BIG3’, as they collectively account for close to half of the premature deaths globally. Thoracic CT screening presents a unique opportunity to integrate care for this high risk cohort with a single imaging examination. We plan to develop optimized protocols for evaluation of these major diseases, explore challenges and define solutions in enabling implementation, especially for economically disadvantaged countries across the world. A core strategy in achieving this ambitious goal is to leverage the use of AI processes across the continuum of care, including its use for risk assessment, disease detection and managing disease interventions.

Planning Committee

Claudia Henschke

PhD, MD

Icahn School of Medicine at Mount Sinai New York, NY

Matthijs Oudkerk

MD, PhD

University of Groningen Groningen, Netherlands

David Yankelevitz

MD

Icahn School of Medicine at Mount Sinai
New York, NY

James Mulshine

MD

Rush University
Chicago, IL

John Field

MA, PhD, BDS, FRCPath

University of Liverpool
Liverpool, United Kingdom

Mario Silva

MD, PhD

University of Parma
Parma, Italy

Witold Rzyman

MD, PhD

Medical University of Gdańsk
Gdańsk, Poland

Program

Thursday, March 19, 2026

08:30–09:00 Introduction to Sessions
Welcome Address: W Rzyman, M Markuszewski, J Kraszewski
09:00–09:30 Research Updates
Meeting Format: C Henschke, M Oudkerk, D Yankelevitz
09:30–10:45

Session 1: Understanding Disease Burden and Integrated Screening in Eastern Europe: Established Programs and Initiatives
Moderators: M Silva, J Chorostowska-Wynimko

  • Poland: M Krzeminski
  • Croatia: K Krpina
  • Czech: M Koziar-Vasakova
  • Greece: G Hardavela
  • Hungary: A Kerpel-Fronius
  • Serbia: M Cavic
  • Slovenia: M Vrankar
10:45–11:00 Coffee Break
11:00–12:00 Session 1: Panel Discussion (AGILE Mission in Eastern Europe)
Moderator: M Silva, D Yankelevitz
Panelists: H Chen, H de Koning, J Field, W Rzyman, E Taioli
12:00–12:45

Session 2: Critical Considerations in Moving Towards Integrated BIG3 Screening
Moderators: J Mulshine, M Oudkerk
Natural course in the absence of screening and impact of early intervention:

  • Lung Cancer: R Yip
  • CVD: P Raggi
  • COPD / Emphysema: L Seijo
12:45–13:45 Session 2: Panel Discussion (What are the shared opportunities?)
Panelists: S Fain, V Liebenberg, S Schmidt, A Stillman, C van der Aalst
13:45–14:45 Lunch Break
14:45–15:35

Session 3: Technology Innovations
Moderators: K Lau, K Kelly

  • Diagnostic Innovations
  • Therapeutic Innovations
  • AI Applications
16:00–16:45 Marilyn and Jim Simons Keynote Lecture
Introduction: C Henschke
Impact of changing image quality on AI performance: R Avila
16:45–17:00 Coffee Break
17:00–17:45 Session 4: Diagnostic Case Review
Moderators: M Jelitto, D Shaham
Panelists: J Gratama, E Kazerooni, A Kerpel-Fronius, K Sienkiewicz, M Silva

Friday, March 20, 2026

 

08:30–09:45

Session 5: Clinical Impact of Early Detection of Cardiovascular Disease
Moderators: A Stillman, P Raggi

 

  • Stroke and Atrial Fibrillation: P Raggi
  • Myocardial Infarction: M van Assen
  • Metabolic syndrome: J Stojanovska
  • Prognostic value of coronary calcium score: M Oudkerk
09:45–10:30

Session 5: Panel Discussion
Introduction: P Raggi

Panelists: J Gratama, M Jaguszewski, SH Lee, M van Assen, A Walstra
10:30–10:45 Coffee Break
10:45–11:45

Session 6: AI for Early Detection of Big 3
Moderators: D Yankelevitz, M Oudkerk

 

  • Comparative AI software validation: K Togka
  • Lung cancer: AI nodule detection and stratification: H Lancaster
  • Ischemic Heart Disease: AI in CAC quantification & localization: A Walstra
  • COPD: AI in LAA Emphysema quantification and cluster characterization: M Silva
11:45–12:30

Session 6: Panel DiscussionModerators: D Yankielevitz, M Oudkerk

Introduction: Risk vs. Diagnosis

Panelists: S Fain, E Kazerooni, L Seijo, A Stillman, S Zheng
12:30–13:30 Lunch Break [ePoster Presentations & Awards]
(for information and submission: agile.eposter@i-dna.org)
Chairs: D Shaham, M Silva
13:30–14:15

Session 7: Biomarker Readiness for Implementation?
Moderators: J Field, J Mulshine

 

  • Extent of Problem and Potential Benefit: C Amos
  • Program Implementation and Challenges: V Liebenberg
  • Workflow Issues with Screening Implementation: S Schmidt
  • Evolution of the use of risk models in lung cancer: S Zheng
14:15–15:00

Session 7: Panel Discussion
Moderators: J Field, J Mulshine

Panelists: C Amos, H de Koning, I Gipp, V Liebenberg, S Schmidt, S Zheng
15:00–15:15 Coffee Break
15:15–16:15

Session 8: Considerations for actionability: invasive vs. non-invasive procedures
Moderators: M Heuvelmans, L Seijo

 

  • Nonsolid: H Chen
  • Part-solid: M Silva
  • Solid: R Yip
16:15–17:00 Session 8: Panel Discussion
Panelists: R Dziedzic, R Dziadziuszko, M Infante, K Lau, W Rzyman, S Senan, JC Trujillo

Saturday, March 21, 2026

09:00–10:00

Session 9: New Therapeutics Approaches
Moderators: C Aigner, W Rzyman

  • Surgery: M Infante
  • Ablation: K Lau
  • Immunotherapy: K Kelly
  • Chemotherapy: N Leighl
  • Radiation Therapy: R Dziadziuszko
10:00–10:45 Session 9: Panel Discussion
Moderators: C Aigner, W Rzyman
Panelists: R Dziadziuszko, N Leight, M Infante, S Senan

10:45–11:35

 

11:35–11:45

Session 10: Therapeutic Case Review
Moderators: W Rzyman, D Yankelevitz
Panelists: C Aigner, D Dziedzic, N Leighl, S Senan

History of the First Elective Lung Resection
11:45–12:15 Coffee Break
12:15–13:15

Session 11: Monitoring Treatment Effectiveness for Stage I Lung Cancers
Moderators: M Oudkerk, L Seijo

  • Post-treatment Follow-up: current guidelines: D Yankelevitz
  • Navigational bronchoscopy: K Lau
  • Tissue acquisition: E Thunnissen
  • Blood test: J Lin
  • Adjuvant therapy for stage I: M Heuvelmans
  • Reoperate vs SBRT: S Senan
13:15–14:15 Lunch Break
14:15–15:00

Session 12: Advocacy in Eastern Europe and the Potential to Collaborate
Moderators: C Heaton, J Mulshine
Panelist: C Bostic, H Koong, K Przewozniak
15:00–15:45 Session 13: New Ideas, Closing Statement, and Future Meetings
C Henschke, M Oudkerk, D Yankelevitz, R Yip

Sponsors

Terms and Conditions

Contact

m.zareba@90consulting.pl

+48 536 770 087

90 Consulting

ul. Bagatela 10/19
Warszawa